Liver CancerNCT06777485
China Liver Cancer Clinical Registry Cohort Database (HEAL)
An observational study of Liver Cancer, run by Anhui Provincial Hospital at 38 sites in China.
Trial summary
This study was led by the Department of Hepatobiliary Surgery of the First Affiliated Hospital of the University of Science and Technology of China (USTC), in close cooperation with many participating units across the country, to establish a standardized clinical information database of hepatocellular carcinoma… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Liver Cancer
- What is being tested?
- Procedure/Surgery treatment and Anti-Tumor Drugs
- Type of treatment
- Surgery or procedure
- How many people
- 10,000 participants
- Where
- 38 sitesChina
- Study dates
- 1 Jan 2025to 1 Jan 2035
- How long will I take part?
- 10 Years
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients diagnosed with hepatocellular carcinoma, intrahepatic cholangiocarcinoma, combined hepatocellular carcinoma-cholangiocarcinoma, or metastatic liver cancer.
Who may be able to join
- Age ≥ 18 years, no gender limit
- Patients without surgery are initially diagnosed with hepatocellular carcinoma, intrahepatic cholangiocarcinoma, mixed hepatocellular carcinoma-cholangiocarcinoma, or metastatic hepatocellular carcinoma based on the results of imaging and laboratory tests, or patients with surgery are diagnosed with hepatocellular carcinoma, intrahepatic cholangiocarcinoma, mixed hepatocellular carcinoma-cholangiocarcinoma, or metastatic hepatocellular carcinoma based on the results of pathologic tests
- Signed informed consent, good compliance, willingness to accept follow-up and provide blood and postoperative pathology residual samples
Who cannot join
- Combination of severe central nervous system disease, respiratory disease, autoimmune disease, chronic renal insufficiency, long-term use of immunosuppressive drugs, combination of severe uncontrolled infections
- Concurrent active cardiovascular disease, cerebrovascular accident within 6 months, myocardial infarction, unstable angina pectoris, or congestive heart failure of class II or greater according to the New York Heart Association criteria, severe arrhythmia requiring medication
- Pregnant or breastfeeding women
- Participation in other therapeutic clinical trials during the course of the patient's illness in which the treatment cannot be specified or information about the treatment cannot be collected
Trial locations and contacts
38 sites in 1 country. Contact the study team or a site near you to ask about taking part.
38 sites in 1 country
China38 sites, 38 recruiting
- Recruiting
Anqing First People's Hospital
Anqing, Anhui, 246000
Zhe Kai, +86 13033189919, kz13033189919@163.com
- Recruiting
Anqing Municipal Hospital
Anqing, Anhui, 246003
Dong-Shu Wang, +86 13500550176
- Recruiting
Bengbu First People's Hospital
Bengbu, Anhui, 233000
Jing Ma, +86 18655258002, 649482245@qq.com
- Recruiting
The First Affiliated Hospital of Bengbu Medical University
Bengbu, Anhui, 233000
Zheng Lu, +86 13721179461, luzhengdr@163.com
- Recruiting
The Second Affiliated Hospital of Bengbu Medical College
Bengbu, Anhui, 233000
Zhao-Long Xu, +86 18009659966, xuzhaolong123@sina.com
- Recruiting
The People's Hospital of Bozhou
Bozhou, Anhui, 236000
Yong-Jian Xu, +86 13605688639, 228441930@qq.com
- Recruiting
The People's Hospital of Chizhou
Chizhou, Anhui, 247000
Sheng-Bing Kong, +86 15339668488, ksbcy2021@126.com
- Recruiting
The First People's Hospital of Chuzhou
Chuzhou, Anhui, 239001
Qing-Song Yang, +86 18955015210, yanchen091106@163.com
- Recruiting
No.2 People's Hospital of Fuyang City
Fuyang, Anhui, 236015
Da-Yong Luo, +86 13805587172, fyldy7172@sina.com
- Recruiting
Fuyang Cancer Hospital
Fuyang, Anhui, 236100
Si-Hua Wu, +86 13965560586, wshdoctor@163.com
- Recruiting
Fuyang Fifth People's Hospital
Fuyang, Anhui, 236100
Ya Guo, +86 18844990001, 147387631@qq.com
- Recruiting
Fuyang People's Hospital
Fuyang, Anhui, 236100
Jun Wang, +86 13956796282, wangjun789456123@163.com
- Recruiting
Fuyang Sixth People's Hospital
Fuyang, Anhui, 236100
Wei-Lin Wang, +86 13955888965, wangdf115@sina.cn
- Recruiting
Funan County People's Hospital
Fuyang, Anhui, 236300
Wei-Guo Wu, +86 13965741588, 8454163@qq.com
- Recruiting
Taihe County People's Hospital
Fuyang, Anhui, 236600
Xin-Ya Zhang, +86 18956716612
- Recruiting
Anhui province hospital
Hefei, Anhui, 230000
Ji-Zhou Wang, MD PhD, +86 13836135864
Lianxin Liu, MD PhD, +86 13845159888, liulx@ustc.edu.cn
- Recruiting
Anhui Provincial Cancer Hospital
Hefei, Anhui, 230000
Cong-Yin Tu, +86 13866107768, tucongyin966@163.com
- Recruiting
Hefei Binhu Hospital
Hefei, Anhui, 230000
Jun Huang, +86 13966740069, hjl716@164.com
- Recruiting
Hefei First People's Hospital
Hefei, Anhui, 230000
Zhong Tong, +86 13965039609, toto6993@163.com
- Recruiting
The First Affiliated Hospital of Anhui Medical University
Hefei, Anhui, 230000
Fu-Bao Liu, +86 13515662646, lancetlfb@126.com
- Recruiting
The Second Hospital of Anhui Medical University
Hefei, Anhui, 230000
Hui Hou, +86 13721026977, 29684293@qq.com
- Recruiting
The Second People's Hospital of Hefei
Hefei, Anhui, 230000
Jun Lu, +86 15309693726, 9458021@qq.com
- Recruiting
Anhui Second People's Hospital
Hefei, Anhui, 230041
Hui-Chun Liu, +86 13909652055, doctorlhc2000@aliyun.com
- Recruiting
Huaibei Mining General Hospital
Huaibei, Anhui, 235000
Zhi-qiang Hu, +86 18056158517, 593865972@qq.com
- Recruiting
Huaibei People's Hospital
Huaibei, Anhui, 235000
Zhi-Gang Chen, +86 18909611127, chenzhigangHB@163.com
- Recruiting
Huainan First People's Hospital
Huainan, Anhui, 232000
Qi Wang, +86 13805549229, wangqihn727@163.com
- Recruiting
Huainan Oriental Hospital
Huainan, Anhui, 232000
Mian Gu, +86 19205540822, 870615197@qq.com
- Recruiting
Huainan Sunshine Xinkang Hospital
Huainan, Anhui, 232000
You-Biao Xu, +86 18955490678, xyb18955490678@qq.com
- Recruiting
Huainan Xinhua Hospital
Huainan, Anhui, 232000
Jian-Kang Yang, +86 13955459952, 95235633@qq.com
- Recruiting
Huangshan City People's Hospital
Huangshan City, Anhui, 242700
Xiao-Chuan Hu, +86 13956269661, 2324991438@qq.com
- Recruiting
Huangshan Shoukang Hospital
Huangshan City, Anhui, 242700
Yan-Hong Weng, +86 13965523066, hsskwyh@sina.com
- Recruiting
Lu'an People's Hospital
Lu'an, Anhui, 237000
Ben-Quan Zhao, +86 13966243721, WPZBQY@163.com
- Recruiting
Suzhou Hospital of Anhui Medical University
Suzhou, Anhui, 234000
Tian-Ming Mei, +86 18225575028, 1403785520@qq.com
- Recruiting
Tongling People's Hospital
Tongling, Anhui, 244000
Ya-Feng Hou, +86 18156210936
- Recruiting
The Second People's Hospital of Wuhu
Wuhu, Anhui, 241000
Dan-Feng Liu, +86 18055316667, dfjx007@163.com
- Recruiting
The First Affiliated Hospital of Wannan Medical College
Wuhu, Anhui, 241001
Xiao-Ming Wang, +86 15922312712, wxm6901@aliyun.com
- Recruiting
Xuancheng People's Hospital
Xuancheng, Anhui, 242000
Wei Cui, +86 18605693628, weicuicuiwei@163.com
- Recruiting
Henan Provincial People's Hospital
Zhengzhou, Henan, 450000
Tao Qin, +86 13949116088, goodfreecn@163.com
About this study
This study was led by the Department of Hepatobiliary Surgery of the First Affiliated Hospital of the University of Science and Technology of China (USTC), in close cooperation with many participating units across the country, to establish a standardized clinical information database of hepatocellular carcinoma cohorts, which will provide a guarantee for conducting high-quality real-world clinical studies and clinical research.
- Conditions
- Liver Cancer
- Being tested
- Procedure/Surgery treatment, Anti-Tumor Drugs
- Medical subject headings
- Liver Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Procedure/Surgery treatmentProcedure or surgery
Routine surgical operations for patients with hepatocellular carcinoma, such as surgical resection, ablation，TACE，HAIC
Anti-Tumor DrugsDrug
Use of anti-tumor drugs, e.g., immunologic, targeted, and chemotherapy drugs
| Study group | Role | What they receive |
|---|---|---|
| Liver Cancer | Observation of clinical routine treatment in patients with Liver cancer Receives: Procedure: Procedure/Surgery treatment; Drug: Anti-Tumor Drugs |
What is being measured
The primary outcome is the main question the study is designed to answer.
OS
Time from enrollment to first recorded occurrence of death from any cause
Measured: 10 years
Secondary outcomes (2)
RFS
Time from enrollment to the first documented occurrence of local, regional, or metastatic liver cancer or death from any cause, whichever occurs first.
Measured: 10 years
Survival time after recurrence
The time from the first documented occurrence of localized, regional, or metastatic liver cancer, whichever occurs first, to death from any cause.
Measured: 10 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Jan 2025
- Study start1 Jan 2025
- Primary completion1 Jan 2035 (estimated)
- Study completion1 Jan 2035 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Liver CancerStudies of the same condition, open and under way.
- More trials run by Anhui Provincial HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 10,000 participants (estimated)
- Target duration
- 10 Years
Sponsor and investigators
- Lead sponsor
- Anhui Provincial Hospital
- Sponsor type
- Other government
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06777485
- Sponsor's protocol ID
- 2024KY585
- Status last verified
- Aug 2025
- First submitted
- 14 Jan 2025
- Last updated
- 20 Aug 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 20 Aug 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- China Liver Cancer Clinical Registry Cohort Database (HEAL)
- ClinicalTrials.gov ID
- NCT06777485
- Acronym / sponsor ID
- 2024KY585
- Conditions
- Liver Cancer
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 10,000 participants (estimated)
- Lead sponsor
- Anhui Provincial HospitalOther government
- Study start
- 1 Jan 2025 (actual)
- Primary completion
- 1 Jan 2035 (estimated)
- Study completion
- 1 Jan 2035 (estimated)
- First posted
- 15 Jan 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study was led by the Department of Hepatobiliary Surgery of the First Affiliated Hospital of the University of Science and Technology of China (USTC), in close cooperation with many participating units across the country, to establish a standardized clinical information database of hepatocellular carcinoma cohorts, which will provide a guarantee for conducting high-quality real-world clinical studies and clinical research.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 10 Years
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Liver Cancer | – | Procedure: Procedure/Surgery treatment, Drug: Anti-Tumor DrugsObservation of clinical routine treatment in patients with Liver cancer |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients diagnosed with hepatocellular carcinoma, intrahepatic cholangiocarcinoma, combined hepatocellular carcinoma-cholangiocarcinoma, or metastatic liver cancer.
Key inclusion criteria (3 listed)
- Age ≥ 18 years, no gender limit
- Patients without surgery are initially diagnosed with hepatocellular carcinoma, intrahepatic cholangiocarcinoma, mixed hepatocellular carcinoma-cholangiocarcinoma, or metastatic hepatocellular carcinoma based on the results of imaging and laboratory tests, or patients with surgery are diagnosed with hepatocellular carcinoma, intrahepatic cholangiocarcinoma, mixed hepatocellular carcinoma-cholangiocarcinoma, or metastatic hepatocellular carcinoma based on the results of pathologic tests
- Signed informed consent, good compliance, willingness to accept follow-up and provide blood and postoperative pathology residual samples
Key exclusion criteria (4 listed)
- Combination of severe central nervous system disease, respiratory disease, autoimmune disease, chronic renal insufficiency, long-term use of immunosuppressive drugs, combination of severe uncontrolled infections
- Concurrent active cardiovascular disease, cerebrovascular accident within 6 months, myocardial infarction, unstable angina pectoris, or congestive heart failure of class II or greater according to the New York Heart Association criteria, severe arrhythmia requiring medication
- Pregnant or breastfeeding women
- Participation in other therapeutic clinical trials during the course of the patient's illness in which the treatment cannot be specified or information about the treatment cannot be collected
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Procedure/Surgery treatmentRoutine surgical operations for patients with hepatocellular carcinoma, such as surgical resection, ablation，TACE，HAIC | Procedure or surgery | Liver Cancer |
| Anti-Tumor DrugsUse of anti-tumor drugs, e.g., immunologic, targeted, and chemotherapy drugs | Drug | Liver Cancer |
Primary outcome
OS
Time frame: 10 years
Time from enrollment to first recorded occurrence of death from any cause
2 secondary outcomes
RFS
Time frame: 10 years
Survival time after recurrence
Time frame: 10 years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Aug 2025.
- Individual participant dataSharing planned: No
Related trials for Liver Cancer
Not yet recruitingPhase 1
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
Colorectal Neoplasms, Neoplasms
RecruitingObservational study
Real-world Evaluation of the HistoSonics Edison System for Treatment of Liver Tumors Across Multidisciplinary Users (BOOMBOX: Master Study)
Liver Neoplasms, Primary Liver Cancer
Recruiting
The Vanguard Study: Testing a New Way to Screen for Cancer
Bladder Carcinoma, Breast Carcinoma
Not yet recruitingPhase 2
SAMe in Prevention of Oxaliplatin-associated Liver Injury
Colorectal Cancer, Liver Metastases
Active, not recruitingPhase 1
Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers
Bladder Carcinoma, Cervical Carcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
38 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Liver Cancer, run by Anhui Provincial Hospital at 38 sites in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 20 Aug 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 38 sites in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Ji-Zhou Wang, MD PhD (+86 13836135864, wangjoe@ustc.edu.cn), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
OS (time frame: 10 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Aug 2025.